ArticleProbiotics and antimicrobial proteins2026
Anti-Bacterial and Anti-Biofilm Activities of Cell-Free Supernatant of Lactobacillus johnsonii Against Salmonella Typhimurium.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Salmonella Typhimurium is a predominant foodborne pathogen whose robust biofilm-forming capacity poses a persistent challenge to food safety and public health. This study investigated the inhibitory effects of cell-free supernatant (CFS) derived from Lactobacillus johnsonii on biofilms and characterized the transcriptional responses associated with CFS exposure using RNA sequencing (RNA-seq). L.johnsonii CFS retarded bacterial growth at high concentrations. Moreover, CFS at various concentrations significantly inhibited biofilm formation in both S. Typhimurium strains, SL1344 and 14028, with maximum inhibition rates of 88.22% and 79.32%, respectively. CFS treatment markedly reduced metabolic activity, surface hydrophobicity, and auto-aggregation, meanwhile impaired bacterial motility and disrupted the architectural integrity of the biofilms. Furthermore, the CFS effectively prevented biofilm formation on various food and food-contact surfaces. RNA-seq analysis revealed that CFS treatment significantly altered the transcriptional profiles of Salmonella, with differentially expressed genes mainly enriched in ribosome, carbon metabolism, oxidative phosphorylation, secondary metabolite biosynthesis, and microbial metabolism in diverse environments. These findings demonstrate the antibiofilm potential of L. johnsonii CFS under laboratory conditions and indicate its potential in controlling Salmonella contamination in food industry.
Indexed as
Identifiers
42909840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.